Production line readiness for high value SAMBA point-of-care Nucleic acid diagnostic test cartridge production.

生产线已做好高价值 SAMBA 护理点核酸诊断测试盒生产的准备。

• 批准号: 102389
• 金额: $ 21.86万
• 依托单位: DIAGNOSTICS FOR THE REAL WORLD (EUROPE) LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2015
• 资助国家: 英国
• 起止时间: 2015 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=102389
• 关键词: Production; line; readiness; value; SAMBA

DRW is marketing a simple, robust point-of-care nucleic acid diagnostic platform, called SAMBA, which allows complex, high-performance tests to be carried out in remote, resource-limited settings in developing countries and primary care settings in developed countries. The first SAMBA tests are for HIV: one to measure HIV viral load for treatment monitoring and one to detect HIV in infants in order to initiate early treatment. Due to WHO recommendation for viral load monitoring and early infant diagnosis in sub-Saharan Africa, the market in the developing world alone will grow to $1 billion/annum by 2017. To meet demand, DRW must automate its test cartridge manufacture to allow a production scale of 1.5 million tests/annum. DRW proposes and requests funding for developing production processes that are appropriate for high-speed assembly and 100% inspection, to produce SAMBA tests for the developed and developing world market.

DRW正在推销一种简单、强大的即时核酸诊断平台SAMBA，该平台允许在发展中国家偏远、资源有限的环境和发达国家初级保健环境中进行复杂、高性能的检测。首批SAMBA检测是针对艾滋病毒的：一种用于测量艾滋病毒载量以进行治疗监测，另一种用于检测婴儿体内的艾滋病毒，以便开始早期治疗。由于世卫组织建议在撒哈拉以南非洲进行病毒载量监测和婴儿早期诊断，到2017年，仅发展中国家的市场就将增长到每年10亿美元。为了满足需求，DRW必须实现测试墨盒制造的自动化，以实现每年150万次测试的生产规模。DRW提议并要求为开发适合高速装配和100%检验的生产工艺提供资金，以便为发达国家和发展中国家市场生产SAMBA测试。